Cargando…

Enhancement of Tumor Radio‐response by Irinotecan in Human Lung Tumor Xenografts

We investigated the ability of 7‐ethyl‐10‐[4‐(l‐piperidino)‐l‐piperidmo]carbonyloxycamptothecin (CPT‐11) to increase tumor radio‐response in vivo using human lung tumor xenografts. The xenografts were treated with (1) CPT‐11 (10 mg/kg) intraperitoneally on days 1, 5 and 9, (2) single dose radiation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamura, Kenji, Takada, Minoru, Kawase, Ichirou, Tada, Takuhito, Kudoh, Shinzoh, Okishio, Kyouichi, Fukuoka, Masahiro, Yamaoka, Naoki, Fujiwara, Yasuhiro, Yamakido, Michio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1997
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921360/ https://www.ncbi.nlm.nih.gov/pubmed/9119752 http://dx.doi.org/10.1111/j.1349-7006.1997.tb00369.x

Ejemplares similares

Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer
por: Takeda, K, et al.
Publicado: (1999)

Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts
por: Kudoh, Shinzoh, et al.
Publicado: (1993)

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995)

Phase I Study and Clinical Pharmacological Evaluation of Daily Oral Etoposide Combined with Carboplatin in Patients with Lung Cancer
por: Ohune, Terumasa, et al.
Publicado: (1995)

No Alteration in DNA Topoisomerase I Gene Related to CPT‐11 Resistance in Human Lung Cancer
por: Ohashi, Nobuyuki, et al.
Publicado: (1996)

Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
por: Negoro, S, et al.
Publicado: (2003)

Prognostic Significance of p53 and ras Gene Abnormalities in Lung Adenocarcinoma Patients with Stage I Disease after Curative Resection
por: Isobe, Takeshi, et al.
Publicado: (1994)

Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft
por: Zuco, Valentina, et al.
Publicado: (2023)

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
por: Masuda, N., et al.
Publicado: (1993)

Differential Expression of DNA Topoisomerase IIα and IIβ Genes between Small Cell and Non‐small Cell Lung Cancer
por: Syahruddin, Elisna, et al.
Publicado: (1998)

Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
por: Kimura, Tatsuo, et al.
Publicado: (2011)

The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitro
por: Takahashi, Toshiaki, et al.
Publicado: (1997)

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy
por: Matsui, Kaoru, et al.
Publicado: (1996)

Determinants of Drug Response in a Cisplatin‐resistant Human Lung Cancer Cell Line
por: Fujiwara, Yasuhiro, et al.
Publicado: (1990)

Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
por: Barbier, Sandrine, et al.
Publicado: (2023)

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)
por: Yamamoto, N, et al.
Publicado: (2004)

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
por: Yamada, M, et al.
Publicado: (2002)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
por: Quackenbush, Kevin S., et al.
Publicado: (2016)

Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts
por: Takahashi, Masamichi, et al.
Publicado: (2019)

Single-treatment tumor ablation with photodynamic liposomal irinotecan sucrosulfate
por: Ghosh, Sanjana, et al.
Publicado: (2022)

Phospho-Aspirin (MDC-22) inhibits pancreatic cancer growth in patient-derived tumor xenografts and KPC mice by targeting EGFR: Enhanced efficacy in combination with irinotecan
por: Rodriguez Lanzi, Cecilia, et al.
Publicado: (2021)

Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts
por: Koga, Yoshikatsu, et al.
Publicado: (2015)

Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer
por: Masuda, Noriyuki, et al.
Publicado: (2010)

Irinotecan Plus Doxorubicin Hydrochloride Liposomes for Relapsed or Refractory Wilms Tumor
por: Wang, Juan, et al.
Publicado: (2021)

Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
por: Yonemori, K, et al.
Publicado: (2009)

Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric MLL-Rearranged Acute Lymphoblastic Leukemia
por: Kerstjens, Mark, et al.
Publicado: (2021)

Applications of patient-derived tumor xenograft models and tumor organoids
por: Yoshida, Go J.
Publicado: (2020)

The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy
por: Greene, Justin, et al.
Publicado: (2017)

Pazopanib radio-sensitization of human sarcoma tumors
por: Wang, Feng, et al.
Publicado: (2018)

Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer
por: Kato, K., et al.
Publicado: (2021)

Former poison gas workers and cancer: incidence and inhibition of tumor formation by treatment with biological response modifier N-CWS.
por: Yamakido, M, et al.
Publicado: (1996)

Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors()
por: Bondarenko, Gennadiy, et al.
Publicado: (2015)

Modeling Lung Carcinoids with Zebrafish Tumor Xenograft
por: Carra, Silvia, et al.
Publicado: (2022)

Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer
por: Bradshaw-Pierce, Erica L., et al.
Publicado: (2013)

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients
por: Chang, T. C., et al.
Publicado: (2015)

Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer
por: Buck, Emanuel, et al.
Publicado: (2019)

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells
por: Reita, Damien, et al.
Publicado: (2019)

A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
por: Yashiro, M, et al.
Publicado: (2013)

Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.
por: Marshall, D., et al.
Publicado: (1994)

Spontaneous pneumothorax due to bronchopleural fistula following reirradiation for locoregionally recurrent squamous cell lung cancer
por: Ota, Takayo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nj545c4ag1898343m3t2dt04vh